Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.62
NAS:CELG's Cash-to-Debt is ranked lower than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:CELG: 0.62 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 10.91 Max: No Debt
Current: 0.62
Equity-to-Asset 0.27
NAS:CELG's Equity-to-Asset is ranked lower than
86% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:CELG: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.77 Max: 0.98
Current: 0.27
-0.68
0.98
Interest Coverage 6.48
NAS:CELG's Interest Coverage is ranked lower than
89% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CELG: 6.48 )
Ranked among companies with meaningful Interest Coverage only.
NAS:CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.33  Med: 27.63 Max: 428.04
Current: 6.48
6.33
428.04
Piotroski F-Score: 5
Altman Z-Score: 4.24
Beneish M-Score: -2.59
WACC vs ROIC
10.28%
21.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 28.05
NAS:CELG's Operating Margin % is ranked higher than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:CELG: 28.05 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CELG' s Operating Margin % Range Over the Past 10 Years
Min: -64.94  Med: 29 Max: 32.84
Current: 28.05
-64.94
32.84
Net Margin % 18.32
NAS:CELG's Net Margin % is ranked higher than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:CELG: 18.32 )
Ranked among companies with meaningful Net Margin % only.
NAS:CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 18.32
-68.02
28.88
ROE % 35.05
NAS:CELG's ROE % is ranked higher than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:CELG: 35.05 )
Ranked among companies with meaningful ROE % only.
NAS:CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 24.32 Max: 33.02
Current: 35.05
-48.42
33.02
ROA % 7.86
NAS:CELG's ROA % is ranked higher than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:CELG: 7.86 )
Ranked among companies with meaningful ROA % only.
NAS:CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.86
-38.07
15.8
ROC (Joel Greenblatt) % 193.05
NAS:CELG's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:CELG: 193.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 212.3
Current: 193.05
-421.4
212.3
3-Year Revenue Growth Rate 22.80
NAS:CELG's 3-Year Revenue Growth Rate is ranked higher than
73% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:CELG: 22.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 22.8
-42.8
241.3
3-Year EBITDA Growth Rate 19.30
NAS:CELG's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:CELG: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 19.35 Max: 295.8
Current: 19.3
-34
295.8
3-Year EPS without NRI Growth Rate 14.00
NAS:CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:CELG: 14.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: 14.7 Max: 109.7
Current: 14
-60.8
109.7
GuruFocus has detected 3 Warning Signs with Celgene Corp $NAS:CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CELG's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CELG Guru Trades in Q2 2016

Ronald Muhlenkamp 19,809 sh (New)
Ken Heebner 20,000 sh (New)
Jim Simons 563,038 sh (New)
Steven Cohen 21,200 sh (New)
Joel Greenblatt 317,274 sh (+360.37%)
Ray Dalio 7,300 sh (+78.05%)
Julian Robertson 379,140 sh (+65.68%)
RS Investment Management 141,861 sh (+27.75%)
Pioneer Investments 4,222,301 sh (+10.49%)
Ken Fisher 204,128 sh (+3.01%)
Murray Stahl 8,000 sh (unchged)
Lee Ainslie Sold Out
Mario Gabelli 26,988 sh (-0.57%)
Eaton Vance Worldwide Health Sciences Fund 139,500 sh (-45.51%)
» More
Q3 2016

CELG Guru Trades in Q3 2016

Paul Tudor Jones 2,500 sh (New)
Signature Select Canadian Fund 34,700 sh (New)
Steven Cohen 249,800 sh (+1078.30%)
Ray Dalio 35,700 sh (+389.04%)
Ronald Muhlenkamp 73,515 sh (+271.12%)
Jim Simons 1,225,638 sh (+117.68%)
Pioneer Investments 4,595,046 sh (+8.83%)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (+218.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Ken Heebner Sold Out
Ken Fisher 199,770 sh (-2.13%)
Julian Robertson 368,940 sh (-2.69%)
Joel Greenblatt 268,338 sh (-15.42%)
Mario Gabelli 15,888 sh (-41.13%)
» More
Q4 2016

CELG Guru Trades in Q4 2016

George Soros 3,500 sh (New)
Steven Cohen 646,900 sh (+158.97%)
Ken Fisher 203,488 sh (+1.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
Ray Dalio Sold Out
Ronald Muhlenkamp 72,688 sh (-1.12%)
Pioneer Investments 4,520,555 sh (-1.62%)
Paul Tudor Jones 2,100 sh (-16.00%)
Julian Robertson 298,740 sh (-19.03%)
Mario Gabelli 11,339 sh (-28.63%)
Jim Simons 751,338 sh (-38.70%)
Joel Greenblatt 119,987 sh (-55.29%)
» More
Q1 2017

CELG Guru Trades in Q1 2017

Ray Dalio 43,412 sh (New)
Jeremy Grantham 1,900 sh (New)
John Burbank 20,710 sh (New)
Stanley Druckenmiller 82,400 sh (New)
David Rolfe 192,000 sh (New)
Joel Greenblatt 158,126 sh (+31.79%)
Pioneer Investments 5,231,139 sh (+15.72%)
Mario Gabelli 12,709 sh (+12.08%)
Murray Stahl 8,000 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
George Soros Sold Out
Ronald Muhlenkamp 72,493 sh (-0.27%)
Ken Fisher 201,869 sh (-0.80%)
Julian Robertson 286,340 sh (-4.15%)
Paul Tudor Jones 1,900 sh (-9.52%)
Steven Cohen 330,000 sh (-48.99%)
Jim Simons 132,138 sh (-82.41%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GILD, NYSE:NVO, NAS:AMGN, OTCPK:SHPGF, NAS:BIIB, NAS:REGN, OTCPK:CSLLY, NAS:VRTX, OTCPK:ALIOY, NAS:INCY, NAS:ALXN, OTCPK:GIKLY, NAS:BMRN, OTCPK:NVZMF, OTCPK:UCBJY, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014.

Top Ranked Articles about Celgene Corp

David Rolfe Gains 3 Holdings, Sells 2 Others in 1st Quarter Guru reports quarterly portfolio
Wedgewood Partners’ David Rolfe (Trades, Portfolio) gained three new holdings during the first quarter and sold two others. His new positions are Edwards Lifesciences Corp. (NYSE:EW), Celgene Corp. (NASDAQ:CELG) and Boeing Co. (NYSE:BA). Read more...

Ratios

vs
industry
vs
history
PE Ratio 43.90
CELG's PE Ratio is ranked lower than
72% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. CELG: 43.90 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 46.03 Max: 603.25
Current: 43.9
17.92
603.25
Forward PE Ratio 16.21
CELG's Forward PE Ratio is ranked higher than
52% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. CELG: 16.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 43.90
CELG's PE Ratio without NRI is ranked lower than
72% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. CELG: 43.90 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.82  Med: 46.01 Max: 482.6
Current: 43.9
17.82
482.6
Price-to-Owner-Earnings 40.03
CELG's Price-to-Owner-Earnings is ranked lower than
54% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. CELG: 40.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 40.17 Max: 922
Current: 40.03
15.44
922
PB Ratio 11.93
CELG's PB Ratio is ranked lower than
91% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CELG: 11.93 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.4 Max: 23.65
Current: 11.93
4.02
23.65
PS Ratio 8.04
CELG's PS Ratio is ranked higher than
58% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CELG: 8.04 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.37  Med: 9.73 Max: 27.97
Current: 8.04
5.37
27.97
Price-to-Free-Cash-Flow 26.15
CELG's Price-to-Free-Cash-Flow is ranked lower than
52% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. CELG: 26.15 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 32.8 Max: 2438.33
Current: 26.15
14.87
2438.33
Price-to-Operating-Cash-Flow 24.52
CELG's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CELG: 24.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.85  Med: 30.92 Max: 1172.5
Current: 24.52
13.85
1172.5
EV-to-EBIT 32.41
CELG's EV-to-EBIT is ranked lower than
71% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CELG: 32.41 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 33.9 Max: 144.7
Current: 32.41
-28.6
144.7
EV-to-EBITDA 27.36
CELG's EV-to-EBITDA is ranked lower than
67% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CELG: 27.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 28.45 Max: 125.5
Current: 27.36
-31.4
125.5
PEG Ratio 2.73
CELG's PEG Ratio is ranked lower than
66% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. CELG: 2.73 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.38  Med: 2.37 Max: 3.26
Current: 2.73
1.38
3.26
Shiller PE Ratio 87.93
CELG's Shiller PE Ratio is ranked lower than
70% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. CELG: 87.93 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 84.46  Med: 140.33 Max: 3211
Current: 87.93
84.46
3211
Current Ratio 4.42
CELG's Current Ratio is ranked lower than
54% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CELG: 4.42 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 7.22 Max: 44.53
Current: 4.42
1.35
44.53
Quick Ratio 4.23
CELG's Quick Ratio is ranked lower than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CELG: 4.23 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 7.03 Max: 44.15
Current: 4.23
1.13
44.15
Days Inventory 406.05
CELG's Days Inventory is ranked lower than
90% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CELG: 406.05 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 104.34  Med: 244.42 Max: 392.21
Current: 406.05
104.34
392.21
Days Sales Outstanding 50.45
CELG's Days Sales Outstanding is ranked higher than
57% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CELG: 50.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.27
Current: 50.45
43.42
71.27
Days Payable 196.81
CELG's Days Payable is ranked higher than
84% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CELG: 196.81 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 139.99 Max: 209.22
Current: 196.81
61.81
209.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CELG: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.3 Max: 4.5
Current: 1.7
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.22
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
57% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. CELG: 2.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.66  Med: 5.6 Max: 124
Current: 2.22
1.66
124
Price-to-Median-PS-Value 0.83
CELG's Price-to-Median-PS-Value is ranked higher than
58% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CELG: 0.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.95 Max: 30
Current: 0.83
0.57
30
Price-to-Peter-Lynch-Fair-Value 2.68
CELG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CELG: 2.68 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.79 Max: 5.1
Current: 2.68
0.36
5.1
Earnings Yield (Greenblatt) % 3.09
CELG's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CELG: 3.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 2.8 Max: 6.7
Current: 3.09
0.7
6.7
Forward Rate of Return (Yacktman) % 19.00
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. CELG: 19.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.1  Med: 2.2 Max: 34.8
Current: 19
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $11,678
EPS (TTM) $ 2.66
Beta1.53
Short Percentage of Float1.20%
52-Week Range $94.42 - 127.64
Shares Outstanding (Mil)780.82

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 13,183 15,542 18,366
EPS ($) 7.33 8.69 10.90
EPS without NRI ($) 7.33 8.69 10.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
20.66%
Dividends per Share ($)
» More Articles for CELG

Headlines

Articles On GuruFocus.com
David Rolfe Gains 3 Holdings, Sells 2 Others in 1st Quarter May 16 2017 
Study These Gurus, but Don’t Buy Their Funds Apr 14 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Celgene Switzerland Invests in Jounce Therapeutics Feb 02 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
9 Stocks Ray Dalio Continues to Buy Dec 22 2016 
When Is the PEG Ratio Superior to the P/E Ratio? Part 2 Nov 03 2016 
Abbott Develops AML Tests With Celgene and Agios Oct 13 2016 
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 

More From Other Websites
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb May 28 2017
I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug May 25 2017
Short Sellers Raise the Stakes in Major Biotechs May 25 2017
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene May 25 2017
Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017 May 25 2017
3 Healthcare Stocks for Savvy Investors May 24 2017
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data May 24 2017
Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with... May 24 2017
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint May 23 2017
Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst May 23 2017
Will Novartis' MS Drug Stomp Celgene's Before It Even Hits The Market? May 22 2017
Celgene's multiple sclerosis drug succeeds in late-stage trial May 22 2017
Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment May 22 2017
Celgene reports positive results in trial of multiple sclerosis treatment May 22 2017
Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral... May 22 2017
5 Leadership Lessons From Exceptionally Successful CEOs May 21 2017
Why Long-Term Investors Should Prefer Celgene Over Biogen May 21 2017
Why Stay Bullish On Gilead May 19 2017
Top 5 Biotech Stocks for 2017 May 19 2017
3 Stocks To Buy When The Market's Crashing May 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)